“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome

We recently found that trastuzumab benefit may be lower in a small subset of early breast cancer (BC) patients (pts) with tumors expressing high levels of both hormonal receptors (HRs), i.e. triple positive (TP). To better investigate the role of HRs in HER2 positive BC, we retrospectively identifie...

Descripción completa

Detalles Bibliográficos
Autores principales: Vici, Patrizia, Pizzuti, Laura, Sperduti, Isabella, Frassoldati, Antonio, Natoli, Clara, Gamucci, Teresa, Tomao, Silverio, Michelotti, Andrea, Moscetti, Luca, Gori, Stefania, Baldini, Editta, Giotta, Francesco, Cassano, Alessandra, Santini, Daniele, Giannarelli, Diana, Di Lauro, Luigi, Corsi, Domenico Cristiano, Marchetti, Paolo, Sini, Valentina, Sergi, Domenico, Barba, Maddalena, Maugeri-Saccà, Marcello, Russillo, Michelangelo, Mentuccia, Lucia, D'Onofrio, Loretta, Iezzi, Laura, Scinto, Angelo Fedele, Da Ros, Lucia, Bertolini, Ilaria, Basile, Maria Luisa, Rossi, Valentina, De Maria, Ruggero, Montemurro, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951261/
https://www.ncbi.nlm.nih.gov/pubmed/26910921
http://dx.doi.org/10.18632/oncotarget.7480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951261/
https://www.ncbi.nlm.nih.gov/pubmed/26910921
http://dx.doi.org/10.18632/oncotarget.7480

Ejemplares similares